We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CBA:ASXCommonwealth Bank of Australia Analysis

Data as of 2026-07-20 - not real-time

A$171.20

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Commonwealth Bank of Australia is trading at a **price‑to‑earnings of 27.5**, well above the industry average of 17.8, indicating that the stock is likely overvalued. The technical picture is mixed: the 20‑day SMA (166.54) sits below the current price (171.2) and the MACD histogram is positive, signaling short‑term bullish momentum, yet the RSI at 61.6 suggests the shares are approaching overbought territory. Volume is decreasing and the price is hovering near the resistance level of 173.72, while support sits at 158.87, leaving limited upside before a pull‑back may be needed. Recent news highlighted a sharp 10% intraday drop – the worst day since March 2020 – and analysts have issued a **sell** recommendation, reflecting heightened market nervousness. Dividend yield remains attractive at 2.88% with a payout ratio of 78%, but operating cash flow is deeply negative (‑45.7 bn), raising questions about the sustainability of those payouts. The market sentiment index reads “Extreme Greed” at 88.5, which, combined with the valuation gap, suggests caution for new entrants.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Recent 10% price plunge and negative sentiment
  • Overvalued P/E relative to peers
  • Technical proximity to resistance with decreasing volume

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Attractive dividend yield but high payout ratio
  • Stable earnings growth (6.6% revenue growth)
  • Continued valuation premium and cash flow weakness

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong market position and brand in Australian banking
  • Potential regulatory and macro‑economic headwinds
  • Long‑term dividend income despite valuation concerns

Key Metrics & Analysis

Financial Health

Revenue Growth6.60%
Profit Margin36.35%
P/E Ratio27.5
ROE13.64%
ROA0.77%
P/B Ratio3.7
Op. Cash FlowA$-45702000640
Industry P/E17.8

Technical Analysis

TrendNeutral
RSI61.6
SupportA$158.87
ResistanceA$173.72
MA 20A$166.54
MA 50A$164.20
MA 200A$165.75
MACDBullish
VolumeDecreasing
Fear & Greed Index88.54

Valuation

Target PriceA$122.59
Upside/Downside-28.39%
GradeOvervalued
TypeValue
Dividend Yield2.88%

Risk Assessment

Beta0.26
Volatility17.51%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.